Company PharmaEngine, Inc.

Equities

4162

TW0004162003

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for PharmaEngine, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
93.3 ^TWD	0.00%		-1.69%	-11.56%

05-02	PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-24	PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors	CI

PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,

TWD in Million	2022	Weight	2023	Weight	Delta
Biopharmaceutical Products 100.0 %	654	100.0 %	768	100.0 %	+17.31%

TWD in Million	2022	Weight	2023	Weight	Delta
Taiwan 100.0 %	654	100.0 %	768	100.0 %	+17.31%

Managers	Title	Age	Since
Hong Ren Wang CEO	Chief Executive Officer	-	-
Yu Syuan Tsao DFI	Director of Finance/CFO	-	16/05/21
Po Nien Shen CTO	Chief Tech/Sci/R&D Officer	-	31/12/12
Chi Hsing Chang IRC	Investor Relations Contact	-	31/01/03
Peter Wu IRO	Public Communications Contact	-	30/06/04
Hui Ying Kuo PRN	Corporate Officer/Principal	-	31/12/12

Members of the board	Title	Age	Since
Jui Wen Wu BRD	Director/Board Member	-	18/01/18
Zhi Li Wang BRD	Director/Board Member	-	12/06/19
Yi Hui Lin BRD	Director/Board Member	-	14/05/18
Jan Yau Hsu CHM	Chairman	-	-
Ming Shiang Wu BRD	Director/Board Member	-	-
Wen Hong Hsu BRD	Director/Board Member	-	-
Ming Feng Hou BRD	Director/Board Member	-	-
Chien Huang Lin BRD	Director/Board Member	-	25/08/21
Ming Daw Chang BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	145,678,200	91,695,240 ( 62.94 %)	2,000,000 ( 1.373 %)	62.94 %

Name	Equities	%	Valuation
First Securities Investment Trust Co. Ltd. 0.3689 %	537,335	0.3689 %	2 M NT$
Hua Nan Securities Investment Trust Co. Ltd. 0.0338 %	49,198	0.0338 %	152 497 NT$
OP Investment Management Ltd. 0.0216 %	31,435	0.0216 %	97 438 NT$
HSBC Global Asset Management (Taiwan) Ltd. 0.0178 %	26,000	0.0178 %	80 591 NT$
Daiwa Asset Management (H.K.) Ltd. 0.0125 %	18,274	0.0125 %	56 643 NT$

PharmaEngine, Inc.

10, Section 3, Minsheng East Road 11th Floor

104 80, Taipei

http://www.pharmaengine.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

93.3 TWD

Average target price

106 TWD

Spread / Average Target

+13.61%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHARMAENGINE, INC.	-11.56%	414M
MODERNA, INC.	+18.21%	47.02B
LONZA GROUP AG	+48.77%	41.86B
IQVIA HOLDINGS INC.	+0.67%	41.76B
CELLTRION, INC.	-4.27%	28.8B
ICON PUBLIC LIMITED COMPANY	+11.99%	26.05B
ALNYLAM PHARMACEUTICALS, INC.	-21.43%	19.15B
BIO-TECHNE CORPORATION	+4.47%	12.55B
MEDPACE HOLDINGS, INC.	+28.46%	12.34B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.48%	11.82B

Other Biotechnology & Medical Research